Table 4.
Comparison of features between patients with COVID-19 vaccine-related and -unrelated Guillain-Barré syndrome.
| Features | COVID-19 vaccine-related GBS |
COVID-19 vaccine-unrelated GBS |
p-value* | |
|---|---|---|---|---|
| (n = 13) | (n = 17) | |||
| Male (%) | 9 (69.2) | 12 (70.6) | 0.936 | |
| Mean age at onset (SD) | 64.1 (19.4) | 63.4 (17.8) | 0.922 | |
| EDX subtype (%) | AIDP | 11 (84.6) | 7 (41.2) | 0.022 |
| AMSAN-AMAN | 2 (15.4) | 9 (52.9) | 0.023 | |
| Normal ENoG | 0 | 1 (5.9) | NA | |
| Infectious antecedent (%) | 0 | 10 (58.2) | 0.001 | |
| Cranial nerves (%) | 4 (30.7) | 7 (41.2) | 0.558 | |
| Ataxia (%) | 3 (15.3) | 4 (23.5) | 0.97 | |
| Autonomic dysfunction (%) | 1 (7.6) | 3 (17.7) | 0.427 | |
| TRF (%) | 3 (23) | 1 (14) | 0.172 | |
| Therapy (%) | IVIg | 10 (76.9) | 11 (64.7) | 0.132 |
| PEX | 1 (7.6) | 3 (17.6) | ||
| IVIg plus PEX | 0 | 3 (17.6) | ||
| No therapy | 2 (15.3) | 0 | ||
| Mean GBS-DS at the last follow up (SD) | 2.53 (1.71) | 2.18 (2.07) | 0.629 | |
| Mortality (%) | 2 (15.4) | 3 (17.6) | 0.869 | |
AIDP, Acute Inflammatory Demyelinating Polyneuropathy; AMAN, Acute Motor Axonal Neuropathy; AMSAN, Acute Motor and Sensory Axonal Neuropathy; EDX, electrodiagnostic; ENoG, electroneurography; GBS, Guillain-Barré syndrome; GBS-DS, Guillain Barré Syndrome Disability Score; IVIg, intravenous immunoglobulins; PEX, plasma-exchange; TRF, treatment related fluctuations; *paired t-test.